Brought to you by 
Kirin licenses Dendreon's dendritic cell technology
19 Nov 2004
Executive Summary
Kirin Brewery Co.'s Pharmaceutical Division received an exclusive license to use Dendreon Corp.'s dendritic cell immunotherapeutic technology in developing therapeutics to market in Japan and many other Asian and Oceanic countries.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Product or Technology Swap
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Kirin licenses Dendreon's dendritic cell technology
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice